Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later across 2 updates Oct 31, 2028 → Feb 28, 2029
See other at-risk trials from University of California, San Francisco

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 1, 2026 to Dec 15, 2026 Show 4 more changesShow less
    • Primary and study completion pushed from Dec 31, 2028 to Feb 28, 2029
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 4 words
  2. Start date: Jul 1, 2026 to Sep 1, 2026
    • Primary and study completion pushed from Oct 31, 2028 to Dec 31, 2028
    v3
  3. Start date: Mar 1, 2026 to Jul 1, 2026
    • Primary and study completion dates: May 31, 2028 to Oct 31, 2028
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
Trial Details
NCT Number NCT07226466
Lead Sponsor University of California, San Francisco
Conditions
(from sponsor)		 Brain Tumor Adult, Brain Metastases From Solid Tumors, Brain Tumor, Primary, Brain Tumor
Related terms Brain Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov